Bioaerosol Science

Bioaerosol Risk Assessment

Assess unintended bioaerosol release and exposure risk from devices, faults, or procedures under controlled study conditions.

We combine capture trains, culture or qPCR endpoints, event logging, and risk modeling to identify pathways and compare mitigation options.

ISO 17025OSHA PELNIOSH RELISO 16000Reviewed 2026-05-16
Request a quoteTalk to a scientist

Purpose & when to use

Bioaerosol Risk Assessment evaluates unintended microbial aerosol release during normal use, misuse, maintenance, faults, or defined procedures. Controlled chambers or enclosures, impingers, filter trains, culture, qPCR, environmental logging, and scenario-based exposure models connect measured release to ISO 17025 records, OSHA PEL or NIOSH REL context, and ISO 16000 sampling strategy. Use this service when bioaerosol exposure risk drives a design, workflow, or mitigation decision:

  1. Medical-device workflow reviews under ISO 17025 records, using breathing-zone capture trains, event timing, and qPCR or culture endpoints to identify emission sources.
  2. Air-treatment mitigation checks aligned to ASHRAE 241, using chamber sampling, device-off baselines, and exposure modeling to compare filters, enclosures, or procedural controls.
  3. Occupational exposure assessments for laboratory or clinical equipment, using OSHA PEL and NIOSH REL context with defined locations, replicates, and background correction.
  4. Indoor-air sampling strategy under ISO 16000, using near-field and room-location samples to document dispersion drivers during maintenance, faults, or aerosol-generating procedures.
  5. Risk-management documentation under ICH Q9, using scenario likelihood, consequence, uncertainty, and measured release data to prioritize design or workflow controls.

Use bioaerosol risk assessment when an efficacy result alone cannot answer where exposure occurs, which event drives release, or whether a mitigation changes the risk profile. The study plan fixes scenarios, sampling positions, endpoints, and decision criteria before testing begins.

Built for devices and workflows with exposure risk

Risk assessments serve products and procedures where operation, misuse, cleaning, or maintenance can generate microbial aerosols. The setup adapts to device geometry, occupational context, and ISO, OSHA, NIOSH, ASHRAE, or ICH decision frames.

  • Medical devicesClinical and patient interfaces
  • Air treatmentRoom and duct mitigation
  • RespiratorsProtection and fit workflows
  • Lab equipmentMaintenance and failure events
  • Spray systemsAerosol-generating procedures

Instrumentation & measurement ranges

Platform selection follows the scenario, biosafety frame, sampling location, and endpoint sensitivity.

1 – 30 mchamber-scale

Controlled chambers and enclosures

Defined test volumes control background conditions, device placement, operator position, ventilation state, and event timing for normal-use, misuse, maintenance, or fault scenarios.

1 – 30 L/minsampler-flow

Impingers and filter capture trains

Timed samplers collect bioaerosols at breathing-zone, near-field, and room locations so concentration and release patterns can be compared across scenarios.

10 – 10000000 copiesquantitation

Culture and qPCR endpoints

Culture and molecular assays convert collected samples into viable counts or gene-copy concentrations, with endpoint choice matched to organism, biosafety limits, and decision need.

1 – 60 minevent-window

Environmental and event logging

Temperature, RH, airflow, device state, operator actions, and event timestamps are logged so measured concentrations can be tied to the release mechanism.

1 – 8 hexposure-window

Scenario exposure modeling

Modeling translates background-corrected concentration data into scenario metrics for exposure comparison, mitigation ranking, and risk-management documentation.

Test method options

MethodStrengthsTradeoffAligned with
Operational emissions and exposure assessment
  • Measures release during representative device operation with ISO 17025 records and ISO 16000 sampling logic for defined background, near-field, and breathing-zone locations.
  • Connects event timing, culture or qPCR results, and scenario modeling to OSHA PEL or NIOSH REL exposure discussions for occupational risk review.
Representative actions, operator position, and sampling windows must be defined before testing, or scenario-to-scenario comparisons lose decision value.
ISO 17025ISO 16000OSHA PELNIOSH REL
Fault, misuse, and procedure-based risk study
  • Captures worst-case release pathways from maintenance, device faults, misuse, or aerosol-generating procedures under ASHRAE 241 infectious-aerosol control context.
  • Supports ICH Q9 risk-management records by linking measured release, uncertainty, mitigation options, and scenario severity in one documented workflow.
Scenario definition and choreography drive the result; ambiguous fault logic or inconsistent timing can dominate measured variability.
ASHRAE 241ICH Q9
Mitigation verification and control comparison
  • Compares enclosures, filters, seals, ventilation settings, or procedural changes against the same baseline using ISO 16000 location strategy and ISO 17025 records.
  • Ranks controls by measured concentration change, exposure-model effect, and implementation assumptions for OSHA PEL, NIOSH REL, or ASHRAE 241 discussions.
Small improvements require stable baseline runs, fixed geometry, and enough replicates to separate mitigation effect from sampler and background variability.
ISO 16000ISO 17025OSHA PELNIOSH RELASHRAE 241

Setup configurations

Every risk assessment starts with the event sequence, device geometry, suspected release pathway, and decision threshold. The configuration defines chamber background, sample locations, replicate logic, endpoint choice, environmental logging, and how each result will feed the exposure or risk model. These setup dimensions are locked in the protocol:

Device interfaces

Device placement, operator position, enclosure geometry, maintenance access, and sampling locations documented with photographs and annotated layouts.

Exposure profile

Normal-use, misuse, fault, or procedure sequence defined with timing, repetitions, device state, and expected release events.

Environmental controls

Background runs, airflow, RH, temperature, ventilation state, and room or chamber conditions logged before and during each scenario.

Sample numbers

Replicates, blanks, background checks, and mitigation comparisons sized to scenario variability and the decision risk.

Chain of custody

Collected samples, organisms or surrogates, extraction records, assay files, devices, and event logs tracked through final report review.

Methods anchored to the standards that matter

Risk assessment studies separate the accredited laboratory quality anchor from aligned exposure, sampling, and occupational-health frames. The anchors below define the study records and reporting language.

  • ISO 17025AccreditedTesting-laboratory competence, calibration traceability, method records, and data review.
  • OSHA PELAlignedOccupational exposure context for interpreting measured concentrations and controls.
  • NIOSH RELAlignedRecommended exposure-limit context for worker-safety risk discussions.
  • ISO 16000AlignedIndoor-air sampling strategy for defined locations, backgrounds, and conditions.

Key data outputs & reporting

Bioaerosol risk assessment reports connect measured release to the scenario that produced it and the decision that follows. Outputs include background-corrected concentrations, event timelines, sampler and assay recovery, exposure-model inputs, mitigation comparisons, uncertainty contributors, method assumptions, and QA / QC evidence needed for biosafety planning, workflow review, engineering-control selection, or risk-management documentation and internal review.

Primary outputs

  • Background-corrected bioaerosol concentration by scenario, sampling location, endpoint, event window, and replicate.
  • Event timeline linking device state, operator action, environmental conditions, and measured concentration changes.
  • Scenario exposure metrics and risk-model inputs with assumptions, uncertainty contributors, and sensitivity notes stated.
  • Mitigation comparison summaries for enclosures, filters, seals, ventilation changes, or procedural controls.

Deliverables

#FormatContents
01PDF reportMethods, scenarios, controls, exposure metrics, mitigation interpretation, and QA / QC.
02CSV / XLSX datasetsConcentrations, event logs, recovery data, model inputs, and replicate summaries.
03FiguresEvent timelines, location comparisons, mitigation overlays, and scenario summaries.

QA / QC & data integrity

Risk assessment studies run with controls that separate true scenario release from background, sampler recovery, assay variability, and timing artifacts. Records are maintained under the ISO 17025 quality system from study setup through final data review, with traceability for instruments, samples, endpoints, scenarios, and model inputs.

Blanks and background runs define chamber or room baseline before scenario release events.

Recovery checks for impingers, filters, extraction steps, and culture or qPCR assays support quantitation limits.

Replicate scenarios and repeated sequences quantify variability across operators, events, or mitigation configurations.

Sampler flow, airflow, RH, temperature, and timing logs are verified against the study record.

Chain of custody tracks collected samples, organisms or surrogates, extracts, devices, and raw data files.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

Quick answers to the questions medical-device teams, air-treatment developers, biosafety officers, industrial hygienists, and clinical workflow groups ask when scoping a bioaerosol risk assessment study. Topics include scenario choice, endpoints, occupational exposure context, mitigation comparisons, modeling assumptions, and deliverables. Reach out if your device geometry, procedure, or regulatory frame does not match the examples below.

Q.Is this the same as an efficacy test?
A.No. Efficacy testing measures how well a device reduces a defined challenge. Risk assessment focuses on unintended release, exposure pathways, scenario likelihood, and whether controls reduce measured or modeled risk.
Q.Can you test misuse or fault scenarios?
A.Yes. We can study normal use, misuse, maintenance, faults, or procedure-based events when the scenario is defined in the protocol with timing, controls, and sampling positions.
Q.Which endpoints do you use?
A.Culture and qPCR are common. Endpoint selection depends on organism, viability question, biosafety requirements, expected concentration, and whether the risk model needs viable counts or gene-copy data.
Q.Do you provide mitigation recommendations?
A.We provide data-driven mitigation options and quantify changes when a control is tested. The report states what the data support and which assumptions remain for implementation.
Q.What do I receive after the assessment?
A.You receive a PDF report, CSV or XLSX datasets, event logs, scenario summaries, figures, QA / QC records, and risk-model inputs suitable for engineering or safety review.

Standards & guidance

Bioaerosol risk assessment is scoped to the exposure, sampling, and risk-management frame that matches the device or procedure under study. ISO 17025 is the accredited quality-system anchor. OSHA PEL, NIOSH REL, ISO 16000, ASHRAE 241, and ICH Q9 are aligned frames used where the scenario, endpoint, and reporting objective fit.

QA & Regulatory - Accredited

ISO 17025

Testing-laboratory competence, documented methods, calibration traceability, uncertainty, and data reviewView standard ->Occupational Exposure - Aligned

OSHA PEL

Occupational exposure-limit context for interpreting measured concentrations and worker-control decisionsView standard ->Occupational Exposure - Aligned

NIOSH REL

Recommended exposure-limit context for occupational health and mitigation discussionsView standard ->Indoor Air - Aligned

ISO 16000

Indoor-air sampling strategy, background control, location selection, and condition documentationView standard ->Bioaerosol & Indoor Air - Aligned

ASHRAE 241

Control of infectious aerosols and equivalent clean airflow context for occupied spacesView standard ->Risk Management - Aligned

ICH Q9

Quality risk-management concepts for scenario likelihood, consequence, uncertainty, and control rankingView standard ->

Related services & devices

Service

Device Challenge Aerosol

Use when the risk model needs a defined aerosol release or detector response checked against reference sampling.Read more ->Devices

Air Treatment

Room, duct, UVGI, and hybrid mitigation devices evaluated for bioaerosol release pathways or control effectiveness.Read more ->Service

Bioaerosol Efficacy Testing Room

Pairs with risk assessment when mitigation effectiveness also needs room-scale microbial reduction data.Read more ->Devices

Medical Devices

Patient-facing and clinical devices where operation, maintenance, or workflow steps can affect bioaerosol exposure.Read more ->Devices

Respiratory

Masks, respirators, PAP devices, and anesthesia systems where exposure pathways and procedure timing shape risk decisions.Read more ->Devices

Spray Aerosol

Spray and aerosol-generating products where inadvertent microbial release or workflow exposure must be characterized.Read more ->